• Home
  • News
  • Semaglutide (Wegovy®) for weight management: Important prescribing information

Semaglutide (Wegovy®) for weight management: Important prescribing information

NCL Wide

On 8 March 2023, the National Institute for Health and Care Excellence (NICE) published guidance recommendations [TA875] on semaglutide (Wegovy®) for managing overweight and obesity within specialist weight management services (including Tier 3 and 4), in line with specific criteria. 

Semaglutide (Wegovy®) is not yet commercially available in the UK.

Patients in primary care should not be prescribed semaglutide (Wegovy® or any other semaglutide preparations) for weight loss, nor be referred into secondary care, until a clear pathway is approved across NCL Integrated Care System.

A review of the prescribing status of semaglutide (Wegovy®) and its position in the treatment pathway will be undertaken by the NCL Joint Formulary Committee.

Expiry date: Sunday, 14 May 2023